Preclinical evaluation and first in human study of Al¹⁸F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer.

ABSTRACT:

Purpose

This study aimed to introduce a novel [¹⁸F]AlF-labeled ODAP-Urea-based Prostate-specific membrane antigen (PSMA) probe, named [¹⁸F]AlF-PSMA-137, which was derived from the successful modification of glutamate-like functional group. The preclinically physical and biological characteristics of the probe were analyzed. Polit clinical PET/CT translation was performed to analyze its feasibility in clinical diagnosis of prostate cancer.

Methods

[¹⁸F]AlF-PSMA-137 was maturely labeled with the [¹⁸F]AlF²⁺ labeling technique. It was analyzed by radio-HPLC for radiochemical purity and stability analysis in vitro and in vivo. The PSMA specificity was investigated in PSMA-positive (LNCaP) and PSMA-negative (PC3)

SUBMITTER: Ren Y 

PROVIDER: S-EPMC9633261 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature